newsfilter
← Latest News
GlobeNewswire·

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

  • Taysha Gene Therapies (NASDAQ: TSHA) will report Q1 2026 financial results & host a corporate update conference call on May 6, 2026, at 8:30 AM ET.
  • The live webcast will be accessible via the Events & Presentations page at ir.tayshagtx.com, with an archived replay available on the company website.
  • Taysha is a clinical-stage biotechnology firm focused on AAV-based gene therapies for severe monogenic diseases of the central nervous system.
  • The company's lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder lacking approved disease-modifying therapies.
  • Taysha utilizes a clinically & commercially proven AAV9 capsid & its manufacturing process to accelerate treatment translation from bench to bedside.
  • Hayleigh Collins serves as Senior Director of Corporate Communications & Investor Relations, while Carolyn Hawley from Inizio Evoke is the media contact.